Before our #UnforgettablePlay pilot tour wraps with 2 final performances in Chicago tomorrow, we’re taking a moment to reflect on its impact. As audiences across the country watched the Davenport family face their matriarch’s Alzheimer’s on stage, new community dialogue started.
“We are tapping into new ways to connect with community. This disease does not discriminate. Treatment, diagnosis and care needs to be available to everyone.” Sarah Lorance, chair of our national board of directors, helps kick off tonight’s #UnforgettablePlay reception. #ENDALZ
“We are in the treatment era, and we're excited. But we have to bond together to ensure that treatment is safe & accessible to all.” Our Chief Diversity, Equity and Inclusion Officer @hillcv17 talks about the importance of healthy equity at tonight’s #UnforgettablePlay reception.
@hillcv17 Our President & CEO @joannepikedrph closed tonight's #UnforgettablePlay reception with the words of Dr. Satcher, the first African American Surgeon General of the U.S.
“The problems are in the community & so are the solutions.”
We are committed to finding the solutions. #ENDALZ
• • •
Missing some Tweet in this thread? You can try to
force a refresh
We welcome and celebrate the @US_FDA Advisory Committee’s unanimous endorsement of the efficacy and clinical benefit of lecanemab (Leqembi) as part of the treatment’s traditional approval process. Read our statement: bit.ly/3WXc7jA.
The next regulatory step toward traditional approval of Leqembi is FDA review, which is required to take place by July 6, 2023.
Last week, @CMSGov said they would cover Alzheimer’s treatments that receive traditional FDA approval if clinicians register and enter data in a registry. We believe registry as a condition of coverage is an unnecessary barrier. We want equitable #AccessNow.